摘要:
The invention concerns compounds of formula (I) wherein: m = 1, 2 or 3; n = 1, 2 or 3; R5 represents a group selected among COR6, CO2R6, SO2R6, SO2NHR6, SO2NHCOR6, SO2NHCO2R6, CONH2, CONHR6; R1, R2, R4, R6, R7 R8 and R12 are as defined in the description, in all their possible isomeric forms, their physiologically acceptable salts, their prodrugs. The invention also concerns the method for preparing them, their use as medicines in particular for treating osteoporosis and the pharmaceutical compositions containing them.
摘要:
The invention concerns compounds of formula (I) wherein: m = 1, 2 or 3; n = 1, 2 or 3; R5 represents a group selected among COR6, CO2R6, SO2R6, SO2NHR6, SO2NHCOR6, SO2NHCO2R6, CONH2 and CONHR6; R1, R2, R4, R5, R6 and R7 are as defined in the description, in all their possible isomeric forms, their physiologically acceptable salts, their prodrugs. The invention also concerns the method for preparing them, their use as medicines in particular for treating osteoporosis and pharmaceutical compositions containing them.
摘要:
The object is to provide a promoting agent for bone formation, a therapeutic method for bone formation and a process for preparing a promoting agent for bone formation. A promoting agent for bone formation which comprises at least one of kistrin, echstatin, a peptide or polypeptide containing the amino acid sequence ArgGlyAsp in the molecule such as a peptide represented by Gly-Arg-Gly-Asp-Ser or a compound represented by general formula (IX) and so on, as well as a biologically acceptable salt thereof, wherein R16 represents -N(R20)2 (R20 represents a hydrogen atom or a C1-C4 alkyl group), R17 represents a hydrogen atom or a C1-C4 alkyl group, R18 represents a hydrogen atom, a C1-C4 alkyl group and so on, R19 represents OH, NH2 and so on, Y represents -NH-, -O- or a direct bond, a represents 1-3, b represents 1 or 2, c represents 0 or 1 and d represents 0 or 1.
摘要:
The invention concerns compounds of formula (I) wherein: m = 1, 2 or 3; n = 1, 2 or 3; R5 represents a group selected among COR6, CO2R6, SO2R6, SO2NHR6, SO2NHCOR6, SO2NHCO2R6, CONH2, CONHR6; R1, R2, R4, R6, R7 R8 and R12 are as defined in the description, in all their possible isomeric forms, their physiologically acceptable salts, their prodrugs. The invention also concerns the method for preparing them, their use as medicines in particular for treating osteoporosis and the pharmaceutical compositions containing them.
摘要:
The invention concerns compounds of formula (I) wherein: X, Y, R1, R2, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compositions containing them.
摘要:
The invention concerns compounds of formula (I) wherein: m = 1, 2 or 3; n = 1, 2 or 3; R5 represents a group selected among COR6, CO2R6, SO2R6, SO2NHR6, SO2NHCOR6, SO2NHCO2R6, CONH2 and CONHR6; R1, R2, R4, R6, R7 and R8 are as defined in the description, in all their possible isomeric forms, their physiologically acceptable salts, their prodrugs. The invention also concerns the method for preparing them, their use as medicines in particular for treating osteoporosis and the pharmaceutical compositions containing them.
摘要:
The invention concerns products of formula (I) in which R1 represents -CONH - [A] - [B] -COR6, [A], [B]; R2, R3, R4, R5 and G are as defined in the description, and their salt additives with acids, bases and esters, the method for preparing them and the intermediates of said method, their application as medicines and the pharmaceutical compositions containing them.